DE10393729T5 - Verfahren zur Behandlung von Emesis - Google Patents

Verfahren zur Behandlung von Emesis Download PDF

Info

Publication number
DE10393729T5
DE10393729T5 DE10393729T DE10393729T DE10393729T5 DE 10393729 T5 DE10393729 T5 DE 10393729T5 DE 10393729 T DE10393729 T DE 10393729T DE 10393729 T DE10393729 T DE 10393729T DE 10393729 T5 DE10393729 T5 DE 10393729T5
Authority
DE
Germany
Prior art keywords
palonosetron
administered
emesis
chemotherapy
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10393729T
Other languages
German (de)
English (en)
Inventor
Alberto Macciocchi
Sergio Cantoreggi
Enrico Braglias
Riccardo Braglias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10393729(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Publication of DE10393729T5 publication Critical patent/DE10393729T5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/23—Updating
    • G06F16/2379—Updates performed during online database operations; commit processing

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Databases & Information Systems (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE10393729T 2002-11-15 2003-11-06 Verfahren zur Behandlung von Emesis Withdrawn DE10393729T5 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42682902P 2002-11-15 2002-11-15
US60/426,829 2002-11-15
PCT/IB2003/005567 WO2004045615A1 (en) 2002-11-15 2003-11-06 Palonosetron for the treatment of chemotherapy-induced emesis

Publications (1)

Publication Number Publication Date
DE10393729T5 true DE10393729T5 (de) 2005-10-13

Family

ID=32326433

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10393729T Withdrawn DE10393729T5 (de) 2002-11-15 2003-11-06 Verfahren zur Behandlung von Emesis

Country Status (6)

Country Link
US (2) US20060079545A1 (enExample)
JP (4) JP5690461B2 (enExample)
AU (1) AU2003302072A1 (enExample)
CA (1) CA2505990C (enExample)
DE (1) DE10393729T5 (enExample)
WO (1) WO2004045615A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303956A1 (en) * 2002-11-05 2004-11-23 Smithkline Beecham Corporation Antibacterial agents
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
EA016455B1 (ru) * 2006-10-24 2012-05-30 Хелсинн Хелткэр С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
JP2010512333A (ja) * 2006-12-07 2010-04-22 ヘルシン ヘルスケア ソシエテ アノニム 塩酸パロノセトロンの結晶及び非晶質形
US20110118189A1 (en) * 2008-04-28 2011-05-19 Farr Stephen J Novel formulations for treatment of migraine
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
EP2499137A1 (en) 2009-11-13 2012-09-19 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
US20160206610A1 (en) * 2015-01-20 2016-07-21 Xoc Pharmaceuticals, Inc. Methods for treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or acute emesis and/or delayed emesis
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US807381A (en) * 1905-01-10 1905-12-12 Auto Stopper Company Means for securing stoppers for vessels in their caps.
US1796729A (en) * 1930-04-18 1931-03-17 Aluminum Co Of America Closure
US2069075A (en) * 1934-04-20 1937-01-26 United Dairies London Ltd Bottle or like container
US2113176A (en) * 1936-03-26 1938-04-05 Guardian Safety Seal Company Sealed receptacle
US3314564A (en) * 1965-05-06 1967-04-18 West Co Container closure
US3601273A (en) * 1969-01-31 1971-08-24 Aluminum Co Of America Pilferproof closure with vertical weakening lines
DE2315962A1 (de) * 1972-04-05 1973-10-18 Metal Closures Ltd Verschlusskappenrohling fuer flaschen od. dgl.
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
AU642178B2 (en) * 1989-11-28 1993-10-14 Roche Palo Alto Llc New tricyclic compounds
GB2277749B (en) * 1993-05-08 1996-12-04 Ciba Geigy Ag Fluorescent whitening of paper
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US20030127420A1 (en) * 2002-01-09 2003-07-10 Klaus Schumacher Dual bottle closure
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride

Also Published As

Publication number Publication date
JP2012131811A (ja) 2012-07-12
JP2016199588A (ja) 2016-12-01
CA2505990C (en) 2009-05-19
JP2006508977A (ja) 2006-03-16
JP6342960B2 (ja) 2018-06-13
JP5893950B2 (ja) 2016-03-23
CA2505990A1 (en) 2004-06-03
AU2003302072A1 (en) 2004-06-15
JP2015143266A (ja) 2015-08-06
US20060079545A1 (en) 2006-04-13
JP5690461B2 (ja) 2015-03-25
US20110178118A1 (en) 2011-07-21
WO2004045615A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
DE60022021T2 (de) Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion
DE69231395T3 (de) Neue medizinische Indikation für Tachykinin-Antagonisten
AT389998B (de) Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung
DE69114470T2 (de) Komposition für die behandlung von augenschmerzen.
DE2362958C2 (de) Pharmazeutische Zusammensetzung zur Linderung von Entzündungen, Fieber oder Schmerzen bei Säugetieren oder zur Senkung des Harnsäurespiegels im Blutserum
CA2505990C (en) Palonosetron for the treatment of chemotherapy-induced emesis
DE3607381A1 (de) Verwendung von diphenylhydantoin und seinen derivaten zur behandlung von immunerkrankungen
DE69931487T2 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
EP0224810B1 (de) Antihypertensives Kombinationspräparat
WO2003099265A2 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
DE2726392A1 (de) Mittel zur bekaempfung der venoesen thrombose
EP1001756B1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
EP0132595B1 (de) Tokolytisches Mittel
DE20320991U1 (de) Dosierungseinheit zur Behandlung von Emesis
DE3213579C2 (enExample)
DE69909395T2 (de) Zusammensetzung mit ketanserin und carnitin zur behandlung von crps
EP2120918B1 (de) Pharmazeutische zusammensetzung zur behandlung von inkontinenz
DE2117762A1 (de) Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung
DE3785953T2 (de) Bakterientötende Gemische.
DE69214647T2 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz
DE3419425A1 (de) Verwendung von d-3-acetoxy-cis-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5h)-on als arzneimittel zur bekaempfung der hypolipidaemie
DE2342214A1 (de) Heilmittel
EP1458389B1 (de) Wässrige lösungen von moxaverin zur behandlung der erektilen dysfunktion
EP0995441A2 (de) Medikamentenkombination zur Therapie der erektilen Dysfunktion
DE4004268A1 (de) Pharmazeutische zubereitung

Legal Events

Date Code Title Description
8181 Inventor (new situation)

Inventor name: MACCIOCCHI, ALBERTO, TAVERNE, CH

Inventor name: BRAGLIA, RICCARDO, PAZALLO, CH

Inventor name: CANTOREGGI, SERGIO, VEZIA, CH

Inventor name: BRAGLIA, ENRICO, PAZALLO, CH

8110 Request for examination paragraph 44
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee